Resveratrol successfully treats experimental endometriosis through modulation of oxidative stress and lipid peroxidation

Citation metadata

Authors: Simsek Yavuz, Nasuhi Aydin, O. Celik, E. Yilmaz, E. Ozerol and K. Tanbek
Date: April-June 2014
From: Journal of Cancer Research and Therapeutics(Vol. 10, Issue 2)
Publisher: Medknow Publications and Media Pvt. Ltd.
Document Type: Report
Length: 4,003 words

Main content

Article Preview :

Byline: Simsek. Yavuz, Nasuhi. Aydin, O. Celik, E. Yilmaz, E. Ozerol, K. Tanbek

Background and Aims: The purpose of this study was to investigate the potential therapeutic efficiency of resveratrol in the treatment of experimental endometriosis in rats. Settings and Design: Experimental study was carried out in a University hospital. Materials and Methods: Endometriosis was surgically induced in 24 female rats. Four weeks after this procedure, the viability and dimensions of the endometriosis foci were recorded. Rats were then randomly divided into three groups: (1) Control group (n = 8); (2) low dose (10 mg/kg) resveratrol group (n = 8); (3) high dose (100 mg/kg) resveratrol group (n = 8). At the end of the 7-day treatment, blood samples were taken and laparotomy was performed. The endometrial implants were processed for biochemical, histological and immunohistochemical studies. Statistical Analysis Used: The Kruskal-Wallis H test and one-way ANOVA test were used. Results: Resveratrol-treated rats showed significantly reduced endometriotic implant volumes (P = 0.004). After treatment, a significant and dose-dependent increase in activities of superoxide dismutase and glutathione peroxidase in serum and tissue of the rats in Group 2 and Group 3 was detected. Similarly, serum and tissue malonyl dialdehyde levels and tissue catalase levels were significantly higher in Group 3 than that of control animals. Histological scores and proliferating cell nuclear antigen expression levels were also significantly reduced in Group 2 and Group 3 than that of control group. Conclusion: In a rat endometriosis model, resveratrol showed potential ameliorative effects on endometriotic implants probably due to its potent antioxidative properties.


Endometriosis is a chronic disease with an unknown etiology, characterized with the presence of the endometrial gland and stroma out of the endometrial cavity. [sup][1],[2] It is mainly a disease of the women of reproductive age and its estimated incidence is 10%. [sup][2],[3] The current consensus is that endometriosis is a local pelvic inflammatory process with altered function of immune-related cells in the peritoneal environment. Supporting this concept are recent studies suggesting that the peritoneal fluid of women with endometriosis contains an increased number of activated macrophages that secrete various local products, such as growth factors, cytokines and possibly free oxygen radicals. [sup][4],[5] A diverse group of agents is used in the medical treatment of endometriosis, however none of these agents have a marked effect upon the disease progress, thus, there is a need to explore new treatment modalities. [sup][4] The new treatment options, such as inhibitors of the arachidonic acid pathway, antioxidant vitamins, proteasome inhibitors (Bortezomib) and nuclear factor-kappa B (NF-kB) inhibitors (Dithiocarbamates) are being investigated for the treatment of endometriosis. [sup][4],[5],[6],[7]

Resveratrol (trans-3, 40, 5-trihydroxystilbene), a natural polyphenolic, non-flavonoid antioxidant, is a phytoalexin found in various food products with particularly high levels in grape skin (50-100 [micro]g/g) and red wine (1.52 mg/l). [sup][8] Resveratrol has been shown to have significant anti-inflammatory, antioxidant and immunomodulatory properties. [sup][9] The anti-inflammatory effects of resveratrol have been demonstrated by suppression of production of reactive oxygen species (ROS) and inhibition of cyclooxygenase-2 (COX-2) expression...

Source Citation

Source Citation
Yavuz, Simsek, et al. "Resveratrol successfully treats experimental endometriosis through modulation of oxidative stress and lipid peroxidation." Journal of Cancer Research and Therapeutics, vol. 10, no. 2, Apr.-June 2014, p. 324. Accessed 31 Mar. 2023.

Gale Document Number: GALE|A377478168